This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
by Zacks Equity Research
NRXS' first-quarter 2026 results show surging revenue and expanding gross margin as reimbursement improves under the Category I CPT code.
NRXSPositive Net Change
earnings medical medical-devices
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
by Moumi Mondal
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
ABTNegative Net Change RHHBYPositive Net Change SYKNegative Net Change
medical medical-devices
Should You Buy Sonic Automotive (SAH) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SAHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Trinity Capital (TRIN) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TRINPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Sensient Technologies (SXT) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
SXTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Sell Stocks for May 15th
by Zacks Equity Research
AVNS, BKR and CAG have been added to the Zacks Rank #5 (Strong Sell) List on May 15th, 2026.
CAGNegative Net Change BKRNegative Net Change AVNSPositive Net Change
medical-devices
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
CAHNegative Net Change MCKNegative Net Change CORPositive Net Change
medical medical-devices
Can ISRG's da Vinci 5 Momentum Sustain Procedure and Utilization Gains?
by Indrajit Bandyopadhyay
ISRG's da Vinci 5 is driving stronger utilization and procedure growth, but can higher throughput and after-hours surgeries sustain momentum?
SYKNegative Net Change ISRGPositive Net Change ZBHNegative Net Change
medical medical-devices
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
by Zacks Equity Research
Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.
ISRGPositive Net Change WSTPositive Net Change GMEDNegative Net Change RVTYPositive Net Change
medical medical-devices
Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
by Zacks Equity Research
DOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.
ISRGPositive Net Change WSTPositive Net Change GMEDNegative Net Change DOCSPositive Net Change
earnings medical medical-devices